AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16634340 — intervention group
Group type: COMPARATOR
Intervention: Wearing the mitt at home every other day for two‐week periods for another three months (in total 21 days).
Number of subjects: 16
Study 16634340 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced group therapy.
Number of subjects: 16
Study 16634340 — intervention group
Group type: COMPARATOR
Intervention: Two‐Point Discrimination Test.
Number of subjects: 16
Study 12741629 — intervention group
Group type: EXPERIMENTAL
Intervention: Combivir (lamivudine 150 mg/zidovudine 300 mg twice daily) + abacavir (300 mg twice daily)
Number of subjects: 195
Study 12741629 — intervention group
Group type: COMPARATOR
Intervention: Combivir (lamivudine 150 mg/zidovudine 300 mg twice daily) + nelfinavir (750 mg every 8 h)
Number of subjects: 195
Study 10800424 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental smoking cessation program
Number of subjects: 454
Study 10800424 — intervention group
Group type: COMPARATOR
Intervention: Control group with minimal smoking cessation interventions
Number of subjects: 454
Study 8776448 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotropic photorefractor with cycloplegia and standard orthoptic examination
Number of subjects: 0
Study 8776448 — intervention group
Group type: EXPERIMENTAL
Intervention: VRP-1 isotropic videorefractor with follow-up refraction under cycloplegia
Number of subjects: 0
Study 8776448 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial refractive correction (spectacle correction)
Number of subjects: 0
Study 8776448 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1457694 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-coated granulated synthetic carbons (30 g, perfusion volume 2.5-3.1 L)
Number of subjects: 14
Study 1457694 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-coated charcoal (27 people)
Number of subjects: 14
Study 1457694 — intervention group
Group type: COMPARATOR
Intervention: Uncoated charcoal (9 people)
Number of subjects: 14
Study 6725033 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 12
Study 6725033 — intervention group
Group type: COMPARATOR
Intervention: Postural drainage and bronchodilator therapy
Number of subjects: 12
Study 6725033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30711177 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue R25 instruments
Number of subjects: 100
Study 30711177 — intervention group
Group type: COMPARATOR
Intervention: Conventional corded electric motor
Number of subjects: 100
Study 30711177 — intervention group
Group type: COMPARATOR
Intervention: Cordless electric motor
Number of subjects: 100
Study 30419942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway implementation for pediatric asthma
Number of subjects: 15
Study 30419942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway implementation for pediatric vomiting and diarrhea
Number of subjects: 15
Study 25178805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted side cut LASIK (130-degree side cut with 150 kHz IntraLase iFS)
Number of subjects: 60
Study 25178805 — intervention group
Group type: COMPARATOR
Intervention: Conventional side cut LASIK (70-degree side cut with 60 kHz IntraLase FS)
Number of subjects: 60
Study 25178805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (inverted and conventional side cut LASIK)
Number of subjects: 60
Study 22975295 — intervention group
Group type: COMPARATOR
Intervention: Nominally aligned condition
Number of subjects: 11
Study 22975295 — intervention group
Group type: EXPERIMENTAL
Intervention: 3° extension alignment change
Number of subjects: 11
Study 22975295 — intervention group
Group type: EXPERIMENTAL
Intervention: 6° extension alignment change
Number of subjects: 11
Study 20377490 — intervention group
Group type: COMPARATOR
Intervention: No anaesthesia
Number of subjects: 100
Study 20377490 — intervention group
Group type: EXPERIMENTAL
Intervention: Perianal lidocaine injection
Number of subjects: 100
Study 20377490 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic lidocaine injection
Number of subjects: 100
Study 20377490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of perianal-intrarectal lidocaine-prilocaine cream
Number of subjects: 100
Study 20377490 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study 18544972 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (60% CHO, 20% protein, 20% fat)
Number of subjects: 8
Study 18544972 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (30% CHO, 20% protein, 50% fat)
Number of subjects: 8
Study 18544972 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal (30% CHO, 50% protein, 20% fat)
Number of subjects: 8
Study 15816568 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate
Number of subjects: 30
Study 14609301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1200 mg daily (3 times 400 mg) for 120 days
Number of subjects: 40
Study 14609301 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 10513096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (combined distant and local acupoints)
Number of subjects: 64
Study 10513096 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 64
Study 8233387 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 241
Study 8233387 — intervention group
Group type: COMPARATOR
Intervention: C3F8 gas
Number of subjects: 241
Study 3689627 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 14824 A (20 mg)
Number of subjects: 8
Study 3689627 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine (cumulative doses of 1.25, 3.75, and 8.75 mg)
Number of subjects: 8
Study 29654039 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 464
Study 29654039 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 464
Study 29654039 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 4 months
Number of subjects: 464
Study 27466360 — intervention group
Group type: EXPERIMENTAL
Intervention: PHE expansion rate (0.31 mL/hour, IQR 0.12-0.55)
Number of subjects: 596
Study 27466360 — intervention group
Group type: EXPERIMENTAL
Intervention: PHE expansion rate
Number of subjects: 596
Study 25828327 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 5433
Study 25828327 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI/CABG
Number of subjects: 5433
Study 25828327 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 5433
Study 23453547 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral fat supplement and fish oil
Number of subjects: 36
Study 23453547 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 36
Study 22287402 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 1, n=60)
Number of subjects: 110
Study 22287402 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg b.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 2, n=50)
Number of subjects: 110
Study 19361602 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (1.5 microg/kg every 20 days for 3 months) plus oral iron
Number of subjects: 30
Study 19361602 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral iron
Number of subjects: 30
Study 16638740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg; 4 doses over 2 days)
Number of subjects: 7
Study 16638740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 7
Study 15571616 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure cut setting
Number of subjects: 49
Study 15571616 — intervention group
Group type: COMPARATOR
Intervention: Blend setting
Number of subjects: 49
Study 11585680 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL‐2 alone (n=13)
Number of subjects: 33
Study 11585680 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐2 + IFN‐alpha (n=5)
Number of subjects: 33
Study 11585680 — intervention group
Group type: COMPARATOR
Intervention: Low-dose IFN‐alpha alone (n=5)
Number of subjects: 33
Study 11585680 — intervention group
Group type: COMPARATOR
Intervention: High-dose IFN‐alpha alone (n=10)
Number of subjects: 33
Study 10408812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml
Number of subjects: 122
Study 10408812 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg/ml
Number of subjects: 122
Study 7853279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies with cerclage (58 pregnancies)
Number of subjects: 35
Study 7853279 — intervention group
Group type: COMPARATOR
Intervention: Pregnancies without cerclage (52 pregnancies)
Number of subjects: 35
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.017% levobunolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% levobunolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.167% levobunolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.017% betaxolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% betaxolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.167% betaxolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 19
Study 2571327 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 1095046 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 8
Study 1095046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31416763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg pro re nata
Number of subjects: 217
Study 31169077 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 456
Study 31169077 — intervention group
Group type: COMPARATOR
Intervention: Cessation pharmacotherapy
Number of subjects: 456
Study 28719527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry-guided remifentanil administration
Number of subjects: 55
Study 28719527 — intervention group
Group type: COMPARATOR
Intervention: Standard remifentanil administration
Number of subjects: 55
Study 25760354 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (hemoglobin level <7.5 g per deciliter)
Number of subjects: 2007
Study 25760354 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion threshold (hemoglobin level <9 g per deciliter)
Number of subjects: 2007
Study 25760354 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold
Number of subjects: 2007
Study 25760354 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion threshold
Number of subjects: 2007
Study 23727832 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual bisection of solid lines
Number of subjects: 0
Study 23727832 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual bisection of letter lines
Number of subjects: 0
Study 23727832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisection by eye fixation of letter lines
Number of subjects: 0
Study 23727832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisection by eye fixation of solid lines
Number of subjects: 0
Study 22205952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal movement counting from gestational week 28
Number of subjects: 1076
Study 22205952 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care not including fetal movement counting
Number of subjects: 1076
Study 18663295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl‐DL‐leucine
Number of subjects: 0
Study 16817839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg o.d.
Number of subjects: 595
Study 16817839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg o.d.
Number of subjects: 595
Study 16817839 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.d.
Number of subjects: 595
Study 12799312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous C-peptide
Number of subjects: 11
Study 12799312 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 12799312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous C-peptide during NOS blockade
Number of subjects: 11
Study 12799312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial C-peptide during NOS blockade
Number of subjects: 11
Study 12799312 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide after recovery from NOS blockade
Number of subjects: 11
Study 11060747 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitiser drugs
Number of subjects: 0
Study 9087576 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegic solution
Number of subjects: 28
Study 9087576 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegic solution
Number of subjects: 28
Study 8328549 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/day
Number of subjects: 24
Study 8328549 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline hydrochloride 1 g/day
Number of subjects: 24
Study 3080289 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 6
Study 3080289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 6
Study 3080289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29880175 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone/30 μg ethinyl estradiol (OC)
Number of subjects: 87
Study 29880175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OC and 1700 mg metformin
Number of subjects: 87
Study 29880175 — intervention group
Group type: EXPERIMENTAL
Intervention: 1700 mg metformin
Number of subjects: 87
Study 29880175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 87
Study 26950683 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g transdermal T gel (TT)
Number of subjects: 31
Study 26950683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral aromatase inhibitor (AI)
Number of subjects: 31
Study 26950683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 24874317 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (texamen) 20 mg daily for 7 days with therapeutic exercises
Number of subjects: 50
Study 24874317 — intervention group
Group type: COMPARATOR
Intervention: Myorelaxants and massage of cervical-collar zone
Number of subjects: 50
Study 22220822 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-metronidazole combination (500 mg of each, three times a day for 7 days) and One-Stage-Full-Mouth-Disinfection (OSFMD)
Number of subjects: 39
Study 22220822 — intervention group
Group type: COMPARATOR
Intervention: Placebo and One-Stage-Full-Mouth-Disinfection (OSFMD)
Number of subjects: 39
Study 20484967 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized tape stripping (SPT)
Number of subjects: 75
Study 20484967 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup of 18 subjects for interrater agreement
Number of subjects: 75
Study 18382081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran for 12 weeks (fiber group)
Number of subjects: 30
Study 18382081 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oat bran)
Number of subjects: 30
Study 15760651 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine (n=6)
Number of subjects: 13
Study 15760651 — intervention group
Group type: COMPARATOR
Intervention: Control (n=7)
Number of subjects: 13
Study 12443955 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock absorbing insoles (two types)
Number of subjects: 9
Study 12443955 — intervention group
Group type: COMPARATOR
Intervention: No insole (control)
Number of subjects: 9
Study 10500075 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA plus budesonide (3 mg three times daily)
Number of subjects: 39
Study 10500075 — intervention group
Group type: COMPARATOR
Intervention: UDCA plus placebo
Number of subjects: 39
Study 10500075 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA plus budesonide
Number of subjects: 39
Study 8934801 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg/day
Number of subjects: 20
Study 8934801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1898300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (50 mg/kg body weight)
Number of subjects: 13
Study 1898300 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.1% BAL)
Number of subjects: 13
Study 1898300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7129725 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating treatment at 45 degrees C
Number of subjects: 10
Study 7129725 — intervention group
Group type: COMPARATOR
Intervention: Non-heated condition
Number of subjects: 10
Study 7129725 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated condition
Number of subjects: 10
Study 31615569 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model to predict 90-day readmission risk
Number of subjects: 350
Study 27858987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg BID (n=54)
Number of subjects: 110
Study 27858987 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycarbamide (n=56)
Number of subjects: 110
Study 27858987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (post hoc analysis)
Number of subjects: 110
Study 27858987 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycarbamide (post hoc analysis)
Number of subjects: 110
Study 27858987 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (after unblinding)
Number of subjects: 110
Study 27858987 — intervention group
Group type: COMPARATOR
Intervention: Hydroxycarbamide
Number of subjects: 110
Study 25926739 — intervention group
Group type: EXPERIMENTAL
Intervention: BPLab® sphygmomanometer
Number of subjects: 30
Study 25926739 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometry
Number of subjects: 30
Study 24461370 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based delivery
Number of subjects: 73
Study 24461370 — intervention group
Group type: COMPARATOR
Intervention: Telehealth-based delivery
Number of subjects: 73
Study 21883458 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning measurements
Number of subjects: 51
Study 21883458 — intervention group
Group type: COMPARATOR
Intervention: Afternoon measurements
Number of subjects: 51
Study 19281327 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Number of subjects: 293
Study 19281327 — intervention group
Group type: COMPARATOR
Intervention: Preemptive antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Number of subjects: 293
Study 19281327 — intervention group
Group type: COMPARATOR
Intervention: Preemptive antifungal treatment
Number of subjects: 293
Study 17290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 1700
Study 17290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1700
Study 17290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nicotine inhaler and bupropion
Number of subjects: 1700
Study 17290726 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (phase 2 trial)
Number of subjects: 1700
Study 17290726 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhaler (phase 2 trial)
Number of subjects: 1700
Study 17290726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (nicotine inhaler and bupropion)
Number of subjects: 1700
Study 17290726 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhaler re-treated with bupropion
Number of subjects: 1700
Study 17290726 — intervention group
Group type: COMPARATOR
Intervention: Bupropion re-treated with nicotine inhaler
Number of subjects: 1700
Study 15318311 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults (Group A)
Number of subjects: 86
Study 15318311 — intervention group
Group type: COMPARATOR
Intervention: Children (Group B)
Number of subjects: 86
Study 15318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal albuminuria (Group C)
Number of subjects: 86
Study 15318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with microalbuminuria (Group D)
Number of subjects: 86
Study 15318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with macroalbuminuria (Group E)
Number of subjects: 86
Study 15318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a well-functioning transplanted kidney (Group F)
Number of subjects: 86
Study 15318311 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with suspected acute rejection (Group G)
Number of subjects: 86
Study 11771440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation therapy following complete resection of gastric cancer
Number of subjects: 0
Study 11771440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy following resection of stage III colon cancer
Number of subjects: 0
Study 11771440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation therapy for stages II and III rectal cancer
Number of subjects: 0
Study 11771440 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy for esophageal cancer
Number of subjects: 0
Study 9158353 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (0.6 microgram/ml, 40 mg/h)
Number of subjects: 9
Study 9158353 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (1.8 micrograms/ml, 120 mg/h)
Number of subjects: 9
Study 9158353 — intervention group
Group type: COMPARATOR
Intervention: Control (no opioid)
Number of subjects: 9